We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Dmh3.0
DMHA (Octodrine) Research
Mostly mechanism / observationalLimited safety
5 peer-reviewed studies
What the evidence says
Mostly mechanism / observational
Most DMHA (Octodrine) studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from mixed-quality studies published 1967–2021.
Based on 5 studies
Confidence
Low
By outcome
Safety, regulation & detection
Mostly mechanism / observational5 studies
Cardiovascular & sympathomimetic risk
Mostly mechanism / observational4 studies
Metabolic / weight-loss claims
Mostly mechanism / observational3 studies
Steady research
1 study in the last 5 years
196719942021
1Observational2021
These cocktails of stimulants have never been tested in humans and their safety is unknown.
The United States Food and Drug Administration banned the stimulant 1,3-dimethylamylamine (1,3-DMAA) from dietary supplements and warned consumers that the stimulant can pose cardiovascular risks ranging from high blood pressure to heart attacks.
Documents the FDA ban of 1,3-DMAA from dietary supplements and the cardiovascular-risk warning (high blood pressure to heart attacks)
States 1,3-DMAA has been investigated as potentially contributing to hemorrhagic strokes and sudden death
Co-authored by the US Department of Defense's military-performance consortium — reflecting the military scrutiny that followed DMAA-linked soldier deaths
3In Vitro2018
Fifteen Aconitum or Kigelia plant samples ... none of them contained 1,5-DMHA ... the enantiomeric distribution and the presence of the synthetic byproducts all suggested the synthetic origin of 1,5-DMHA in the commercial products.
Wang M, Haider S, Chittiboyina AG, Parcher JF, Khan IA · Journal of pharmaceutical and biomedical analysis (2018)
Counter-evidence to the marketing claim that DMHA is a 'natural' constituent of Aconitum or Kigelia plants — none of 15 plant samples contained it within the detection limit
DMHA in supplements was racemic and carried synthesis byproducts, indicating a synthetic, poor-quality source rather than a botanical extract
One product contained up to 112 mg per serving — over three times the highest European pharmaceutical dose
Octodrine is the trade name for Dimethylhexylamine (DMHA), a central nervous stimulant that increases the uptake of dopamine and noradrenaline ... Reported side-effects include hypertension, dyspnoea and hyperthermia.
Catalani V, Prilutskaya M, Al-Imam A, Marrinan S, Elgharably Y, Zloh M, et al. · Brain sciences (2018)
First pharmacology-focused review of octodrine/DMHA in seven decades — characterizes it as a CNS stimulant increasing dopamine and noradrenaline uptake, originally a 1950s nasal decongestant
Only five relevant scientific publications existed; most user information came from bodybuilding fora marketing it as 'the god of stimulants'
Reported harms include hypertension, dyspnoea, and hyperthermia, with concern about athlete safety and doping